Key Highlights

  • Shares declined 9.59% to USD 4.15 in premarket trading on November 4, 2026, a fall of USD 0.4402.
  • Third quarter 2026 Revenue dropped 19% to USD 24.6 million from USD 30.3 million a year earlier.
  • Light Adjustable Lens Volume decreased 11% to 23,128 units from 26,045 units.
  • Gross Margin was 73.6%, compared with 79.9% in the third quarter of 2025.
  • The net loss was USD 16.2 million, or USD 0.39 per share, versus USD 9.8 million, or USD 0.24 per share.

What Moved RxSight Before the Open (down USD 0.4402, 9.59%)

RxSight (NASDAQ:RXST) traded 9.59% lower at USD 4.15 in premarket trading on November 4, 2026, a decline of USD 0.4402 from an implied Tuesday, November 3, 2026 close of about USD 4.59 (calculated from the screen figures). The move came after the company released its third quarter 2026 results following the regular Trading session on November 3, 2026.

The report showed a double-digit revenue decline, a lower gross margin and a wider loss, and the company gave no financial guidance. Management put the weakness mainly down to competitive pressure.

The Third Quarter Results in Detail

According to the company press release dated November 3, 2026, total revenue for the quarter ended September 30, 2026 came to USD 24.6 million, of which product sales were USD 24.5 million. That compares with USD 30.3 million in the third quarter of 2025. Nine-month revenue was USD 89.2 million, versus USD 101.9 million a year earlier.

On the earnings call, management said Light Adjustable Lens procedure revenue was USD 22.8 million and that volume fell 11% to 23,128 units. Gross margin slipped to 73.6% from 79.9%, a change the company linked mainly to higher inventory reserves.

Selling, general and administrative expenses were USD 27.4 million and Research and Development was USD 9.2 million. The operating loss widened to USD 18.5 million from USD 12.2 million. Adjusted net loss, which excludes stock-based compensation, was USD 8.6 million, or USD 0.21 per share, compared with USD 1.7 million, or USD 0.04 per share.

Business Background and Management Commentary

RxSight is a medical technology company. Its Light Adjustable Lens is an intraocular lens for cataract surgery that surgeons can fine-tune after implantation using a light delivery device.

On the call, management pointed to three factors behind the soft quarter: seasonality, competition and disruption from a near doubling of the sales organization. The company completed a restructuring of its manufacturing, corporate and international functions. It did not quantify savings, but expects 2027 operating expenses to be lower than in 2026.

Light delivery device placements are now a lower priority, with three sales and one rental in the quarter. Management expects fourth quarter lens sales to rise mid to high single digits from the third quarter, based on reduced seasonality and October trends.

Balance Sheet, Alcon Agreement and Risks

Cash, cash equivalents and short-term investments totaled USD 254.7 million at September 30, 2026. That figure includes USD 60 million received in the third quarter under a collaboration with Alcon (NYSE:ALC). The Balance Sheet also carries a USD 50.0 million refund liability. The initial 120-day period under the agreement has passed, which finalizes the upfront payment.

With the shares below USD 5, the stock can be highly volatile and may trade with limited liquidity, and any future Equity raise could dilute existing holders.

What to Watch Next

Investors will look for fourth quarter lens volume against the guided sequential increase, the first full year guidance expected with fourth quarter results in early 2027, and evidence that the restructuring is lowering expenses.